rs61764370
| Orientation | minus |
| Stabilized | minus |
| Geno | Mag | Summary |
|---|---|---|
| (T;T) | 0 | common in clinvar |
| Make rs61764370(G;G) |
| Make rs61764370(G;T) |
| Reference | GRCh38 38.1/141 |
| Chromosome | 12 |
| Position | 25207290 |
| Gene | KRAS |
| is a | snp |
| is | mentioned by |
| dbSNP | rs61764370 |
| dbSNP (classic) | rs61764370 |
| ClinGen | rs61764370 |
| ebi | rs61764370 |
| HLI | rs61764370 |
| Exac | rs61764370 |
| Gnomad | rs61764370 |
| Varsome | rs61764370 |
| LitVar | rs61764370 |
| Map | rs61764370 |
| PheGenI | rs61764370 |
| Biobank | rs61764370 |
| 1000 genomes | rs61764370 |
| hgdp | rs61764370 |
| ensembl | rs61764370 |
| geneview | rs61764370 |
| scholar | rs61764370 |
| rs61764370 | |
| pharmgkb | rs61764370 |
| gwascentral | rs61764370 |
| openSNP | rs61764370 |
| 23andMe | rs61764370 |
| SNPshot | rs61764370 |
| SNPdbe | rs61764370 |
| MSV3d | rs61764370 |
| GWAS Ctlg | rs61764370 |
| GMAF | 0.04362 |
| Max Magnitude | 0 |
[PMID 21385923
] Contrary to the claims of a test being marketed, a large study (8,500+ patients and >10,000 controls) found no evidence for any association between rs61764370 and any form of ovarian cancer.
[PMID 20676756] Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families
[PMID 21435948] A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis
This letter in the Lancet challenges the claims of an association with triple-negative breast cancer in [PMID 21435948]
[PMID 22679560] KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer
[PMID 20647319] A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.
[PMID 21807336] Association between KRAS rs61764370 and triple-negative breast cancer--a false positive?
[PMID 22003074] KRAS rs61764370 in Epithelial Ovarian Cancer-Letter.
[PMID 22584434] High Let-7a MicroRNA Levels in KRAS-Mutated Colorectal Carcinomas May Rescue Anti-EGFR Therapy Effects in Patients with Chemotherapy-Refractory Metastatic Disease.
[PMID 23167843] Let-7 miRNA-binding site polymorphism in the KRAS 3`UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab
[PMID 24282149] Targeted Knock-in of the Polymorphism rs61764370 does not Affect KRAS Expression but Reduces let-7 Levels
[PMID 23010532] No evidence for genetic association with the let-7 microRNA-binding site or other common KRAS variants in risk of endometriosis.
[PMID 23324806] The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients.
[PMID 25081901] A 3'UTR KRAS variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
[PMID 25183481] A let-7 microRNA-Binding Site Polymorphism in KRAS Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab Monotherapy
[PMID 26515332] KRAS polymorphisms are associated with survival of CRC in Chinese population
[PMID 27221928] The rs61764370 Functional Variant in the KRAS Oncogene is Associated with Chronic Myeloid Leukemia Risk in Women.
| ClinVar | |
|---|---|
| Risk | rs61764370(G;G) |
| Alt | rs61764370(G;G) |
| Reference | Rs61764370(T;T) |
| Significance | Probable-non-pathogenic |
| Disease | Cardio-facio-cutaneous syndrome Noonan syndrome |
| Variation | info |
| Gene | KRAS |
| CLNDBN | Cardio-facio-cutaneous syndrome Noonan syndrome |
| Reversed | 1 |
| HGVS | NC_000012.11:g.25360224A>C |
| CLNSRC | |
| CLNACC | RCV000287744.1, RCV000384527.1, |
